Cue Biopharma, Inc. Balance Sheet
CUE|8 years of annual SEC 10-K data (FY2018-FY2025)
Shows total assets, cash and equivalents, receivables, property and equipment, total debt, and shareholders' equity across 8 fiscal years. All figures from audited SEC 10-K filings.
Cue Biopharma, Inc. had $42M in total assets and $26M in shareholders' equity as of FY2025.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score -7.60 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $27.1M | $22.5M | $48.5M | $51.6M | $64.4M | $74.9M | $44.3M | - |
| Accounts Receivable | $5.5M | $945.0K | $1.7M | $57.0K | $3.1M | $1.4M | $754.9K | - |
| Current Assets | $37.0M | $25.1M | $51.5M | $77.2M | $68.5M | $87.5M | $61.0M | $40.6M |
| PP&E (Net) | $241.0K | $471.0K | $795.0K | $1.5M | $2.1M | $2.1M | $1.8M | $2.8M |
| Total Assets | $42.2M | $32.2M | $61.5M | $91.3M | $83.4M | $99.5M | $71.6M | $45.4M |
| Current Liabilities | $13.5M | $13.7M | $17.1M | $11.5M | $12.8M | $16.3M | $11.7M | $6.2M |
| Total Debt | - | $0 | $4.0M | $8.0M | $0 | - | - | - |
| Shareholders' Equity | $26.4M | $17.5M | $37.1M | $65.7M | $65.5M | $54.6M | $34.0M | $15.2M |